Aon Boosts Data Center Insurance Capacity by $1B to $2.5B
Aon has expanded its Data Center Lifecycle Insurance Program by $1 billion, raising total underwriting capacity to $2.5 billion to address growing AI, cloud computing and digital infrastructure investments. The enhanced multi-line solution integrates construction, cyber, cargo and operational risk coverage to support large-scale data center construction and operations globally.
1. Aon Expands Data Center Lifecycle Insurance Capacity to $2.5 Billion
On January 14, 2026, Aon announced a $1 billion increase in capacity for its Data Center Lifecycle Insurance Program (DCLP), bringing total coverage to $2.5 billion. Launched in 2025, DCLP integrates construction all risks, cyber property damage, cargo and operational business interruption into a single solution. The expanded program offers up to $2.5 billion for construction and operational property damage, $400 million for cyber and technology E&O exposures, $100 million in third-party liability (excluding U.S. exposures) and $500 million for project cargo. By coupling risk engineering and cyber impact modelling from Aon’s Global Risk Consulting team with enhanced capacity, the firm aims to streamline underwriting for large-scale data center projects, accelerate build-out timelines and bolster resilience in the face of complex digital-infrastructure risks.
2. GLP-1 Research Reveals Employer Cost Savings and Reduced Cancer Risk for Women
Building on its April 2025 study, Aon’s latest analysis of medical and pharmacy claims for over 192,000 GLP-1 users shows sustained therapy adherence drives meaningful financial and clinical outcomes. Employers whose employees maintained at least 80 percent adherence saw medical cost growth six to nine percentage points lower over 30 months for diabetes indications, and three to seven points lower at 18 months for weight-loss prescriptions. Female users experienced a 47 percent reduction in hospitalizations for major cardiovascular events, a roughly 50 percent lower incidence of ovarian cancer and a 14 percent lower incidence of breast cancer compared to matched non-users. As prescription drug costs rise near 13–15 percent annually, with GLP-1 therapies now comprising 20 percent of total drug spend, Aon’s findings underscore the potential for targeted benefit design and adherence programs to deliver long-term savings and workforce health improvements.